Nektar Therapeutics Secures $460 Million in Successful Public Stock Offering
On February 13, 2026, Nektar Therapeutics (Nasdaq: NKTR), a biotechnology firm specializing in immunotherapy solutions, announced the completion of its significant public stock offering, raising an impressive $460 million. This capital infusion will play a crucial role in accelerating the development of novel medicines designed to tackle immunological disorders.
The details of the offering revealed that a total of 7,637,931 shares of common stock were sold at a public price of $58.00 each. Moreover, this figure includes approximately 1,034,482 additional shares that the underwriters opted to purchase as part of their commitment to the offering. Nektar also offered pre-funded warrants to investors, priced at $57.9999 each, reflecting the market's robust interest in its stock. The total gross proceeds from this public offering amount to around $460 million, subject to standard underwriting discounts, commissions, and associated expenses.
This successful transaction saw Jefferies, TD Cowen, and Piper Sandler serve as the joint book-running managers. They were supported by Oppenheimer & Co. and H.C. Wainwright & Co. as lead managers, assigning B. Riley Securities as the offering manager. This collaboration underscores the collective confidence in Nektar's vision and the strategic potential of its therapeutic innovations.
The securities offered were made available under a shelf registration statement with the SEC, automatically activating upon submission on November 12, 2025. Thus, the offering proceeded seamlessly, with necessary materials filed appropriately with regulatory bodies.
Nektar Therapeutics is dedicated to addressing pressing healthcare needs in the realm of autoimmune and chronic inflammatory diseases. The company’s flagship candidate, rezpegaldesleukin (REZPEG or NKTR-358), is at the forefront of its pipeline. This innovative regulatory T cell stimulator is currently being evaluated in multiple Phase 2b clinical trials targeting conditions such as atopic dermatitis and alopecia areata, in addition to a Phase 2 study focused on Type 1 diabetes.
Nektar’s research portfolio also features various promising assets including a bivalent tumor necrosis factor receptor type II (TNFR2) antibody and two bispecific programs: NKTR-0165 and NKTR-0166. Another noteworthy investigational product in Nektar's lineup, NKTR-255, is an IL-15 receptor agonist aiming to enhance the immune system's capacity to combat cancer, and it is currently under investigation in various clinical trials.
Nektar operates out of its headquarters in San Francisco, California, reinforcing its commitment to fostering innovation in the biotechnology landscape. With this new wave of funding, the company is well-poised to accelerate its research and development endeavors and ultimately improve therapeutic options for patients facing debilitating diseases.
For stakeholders keen on observing Nektar's trajectory, the SEC maintains access to the final prospectus supplement alongside the accompanying prospectus materials related to this offering on its official website. Additionally, qualified individuals can directly approach the underwriters for copies and further inquiries regarding the prospectus.
This strategic financial move aligns well with Nektar’s ongoing mission to innovate within the field of immunotherapy and alleviates some of the financial constraints that often hamper research in biotechnology. As healthcare continues to evolve, investments like this are pivotal in paving the way for advancements that can significantly improve patient outcomes.
The details of the offering revealed that a total of 7,637,931 shares of common stock were sold at a public price of $58.00 each. Moreover, this figure includes approximately 1,034,482 additional shares that the underwriters opted to purchase as part of their commitment to the offering. Nektar also offered pre-funded warrants to investors, priced at $57.9999 each, reflecting the market's robust interest in its stock. The total gross proceeds from this public offering amount to around $460 million, subject to standard underwriting discounts, commissions, and associated expenses.
This successful transaction saw Jefferies, TD Cowen, and Piper Sandler serve as the joint book-running managers. They were supported by Oppenheimer & Co. and H.C. Wainwright & Co. as lead managers, assigning B. Riley Securities as the offering manager. This collaboration underscores the collective confidence in Nektar's vision and the strategic potential of its therapeutic innovations.
The securities offered were made available under a shelf registration statement with the SEC, automatically activating upon submission on November 12, 2025. Thus, the offering proceeded seamlessly, with necessary materials filed appropriately with regulatory bodies.
Nektar Therapeutics is dedicated to addressing pressing healthcare needs in the realm of autoimmune and chronic inflammatory diseases. The company’s flagship candidate, rezpegaldesleukin (REZPEG or NKTR-358), is at the forefront of its pipeline. This innovative regulatory T cell stimulator is currently being evaluated in multiple Phase 2b clinical trials targeting conditions such as atopic dermatitis and alopecia areata, in addition to a Phase 2 study focused on Type 1 diabetes.
Nektar’s research portfolio also features various promising assets including a bivalent tumor necrosis factor receptor type II (TNFR2) antibody and two bispecific programs: NKTR-0165 and NKTR-0166. Another noteworthy investigational product in Nektar's lineup, NKTR-255, is an IL-15 receptor agonist aiming to enhance the immune system's capacity to combat cancer, and it is currently under investigation in various clinical trials.
Nektar operates out of its headquarters in San Francisco, California, reinforcing its commitment to fostering innovation in the biotechnology landscape. With this new wave of funding, the company is well-poised to accelerate its research and development endeavors and ultimately improve therapeutic options for patients facing debilitating diseases.
For stakeholders keen on observing Nektar's trajectory, the SEC maintains access to the final prospectus supplement alongside the accompanying prospectus materials related to this offering on its official website. Additionally, qualified individuals can directly approach the underwriters for copies and further inquiries regarding the prospectus.
This strategic financial move aligns well with Nektar’s ongoing mission to innovate within the field of immunotherapy and alleviates some of the financial constraints that often hamper research in biotechnology. As healthcare continues to evolve, investments like this are pivotal in paving the way for advancements that can significantly improve patient outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.